The USA pays substantially more for the same branded drug compared with other high-income nations, with estimates suggesting the USA pays three to five times the price compared with most European ...

The authors argue that sustainable drug pricing reform should focus on patient-centered value, not price alone. IRP is a government price-control mechanism utilized worldwide, where a country ...

Pharmaceutical companies have been cautioned that the Trump administration is looking at introducing a policy to link the prices of U.S. medicines to the levels they are available in other developed ...

The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. What Happened: The Trump Administration is contemplating a policy to align ...

Government health officials told source they were exploring an international reference pricing policy U.S. pays nearly three times more than other developed countries for drugs The policy is more ...

FTC settlement frameworks for major PBMs mandate transparency to plan sponsors, fee-based remuneration, limits on spread pricing, and reshoring of offshore GPO functions, but allow employer opt-outs.

On 12 May 2025, US President Donald Trump signed an executive order directing the US Department of Health and Human Services (HHS) to secure Most Favored Nation (MFN) pricing for medicines. Central to ...

The concept rests on assumptions that are unsupported by evidence. Consequently, current proposals for mandatory international reference pricing will not reduce drug costs for most patients. The Trump ...